Century Therapeutics’ (IPSC) “Buy” Rating Reiterated at Guggenheim

Century Therapeutics (NASDAQ:IPSC)‘s stock had its “buy” rating reiterated by analysts at Guggenheim in a research note issued on Friday,Benzinga reports.

Other equities research analysts have also issued research reports about the company. Chardan Capital dropped their price target on Century Therapeutics from $11.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Piper Sandler decreased their price objective on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Thursday, March 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Century Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $5.00.

Century Therapeutics Trading Down 0.4 %

Shares of IPSC traded down $0.00 on Friday, reaching $0.55. 4,837 shares of the company’s stock were exchanged, compared to its average volume of 379,223. The business has a 50 day moving average price of $0.71 and a two-hundred day moving average price of $1.13. Century Therapeutics has a 12 month low of $0.52 and a 12 month high of $4.43. The stock has a market capitalization of $46.98 million, a P/E ratio of -0.30 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The company had revenue of $4.18 million for the quarter, compared to the consensus estimate of $0.67 million. Equities research analysts predict that Century Therapeutics will post -1.61 EPS for the current year.

Institutional Trading of Century Therapeutics

Several hedge funds have recently added to or reduced their stakes in IPSC. Marshall Wace LLP bought a new position in Century Therapeutics during the 4th quarter worth $36,000. Jane Street Group LLC increased its position in Century Therapeutics by 166.2% during the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after acquiring an additional 29,992 shares during the period. Two Sigma Advisers LP bought a new position in Century Therapeutics during the fourth quarter worth about $52,000. Sei Investments Co. acquired a new stake in Century Therapeutics in the 4th quarter worth about $53,000. Finally, Two Sigma Investments LP bought a new stake in Century Therapeutics in the 4th quarter valued at about $67,000. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.